{"name":"Ivan Šitum, MD","slug":"ivan-itum-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Continuos ceftazidime/avibactam infusion","genericName":"Continuos ceftazidime/avibactam infusion","slug":"continuos-ceftazidime-avibactam-infusion","indication":"Complicated urinary tract infections (cUTI) including pyelonephritis","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Intermitent dosing as per SMPC","genericName":"Intermitent dosing as per SMPC","slug":"intermitent-dosing-as-per-smpc","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Continuos ceftazidime/avibactam infusion","genericName":"Continuos ceftazidime/avibactam infusion","slug":"continuos-ceftazidime-avibactam-infusion","phase":"marketed","mechanism":"Ceftazidime/avibactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.","indications":["Complicated urinary tract infections (cUTI) including pyelonephritis","Complicated intra-abdominal infections (cIAI)","Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)","Carbapenem-resistant Enterobacteriaceae (CRE) infections"],"catalyst":""},{"name":"Intermitent dosing as per SMPC","genericName":"Intermitent dosing as per SMPC","slug":"intermitent-dosing-as-per-smpc","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}